Snyder, Christopher
(2023)
Expanded Access and Insights from the Pioneering Work of Dr. Thomas E. Starzl.
(Unpublished)
Abstract
Expanded Access is a program designed to connect patients with experimental therapeutics when no other FDA-approved options are available for their given disease. In the 1980s, Dr. Thomas E Starzl, the father of modern organ transplantation, pursued the development and approval of multiple experimental immunosuppression compounds to prevent acute organ rejection in transplant patients. We will examine a historical case study of Dr. Starzl’s work with OKT-3 (muromonab) which will provide context for a discussion regarding the degree of autonomy we should grant physicians to make ethical decisions in critical Expanded Access cases, as well as the amount of oversight necessary to protect these vulnerable patients. Although this case is historical, we may gain insight into the modern problem of Expanded Access which parallels Dr. Starzl’s compassionate use requests for experimental therapies nearly three decades ago.
Share
Citation/Export: |
|
Social Networking: |
|
Details
Item Type: |
Article
|
Status: |
Unpublished |
Creators/Authors: |
|
Contributors: |
Contribution | Contributors Name | Email | Pitt Username | ORCID |
---|
Collaborator | Brodt, Zachary | zlb2@pitt.edu | UNSPECIFIED | UNSPECIFIED | Collaborator | Rampelt, Jason | rampelt@pitt.edu | UNSPECIFIED | UNSPECIFIED | Collaborator | Zautra, Nicholas | ngz4@pitt.edu | UNSPECIFIED | UNSPECIFIED |
|
Date: |
26 May 2023 |
Refereed: |
No |
Article Type: |
Research Article |
Additional Information: |
Research made possible by the Archival Scholars Research Award (ASRA) 2023 |
Date Deposited: |
31 May 2023 14:01 |
Last Modified: |
31 May 2023 14:01 |
URI: |
http://d-scholarship.pitt.edu/id/eprint/44912 |
Metrics
Monthly Views for the past 3 years
Plum Analytics
Actions (login required)
|
View Item |